Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.

Humans Male Female Adolescent Young Adult Adult Middle Aged Aged Aged, 80 and over Prospective Studies France / epidemiology Breast Neoplasms / diagnosis
access cancer early-phase clinical trial social inequalities

Journal

ESMO open
ISSN: 2059-7029
Titre abrégé: ESMO Open
Pays: England
ID NLM: 101690685

Informations de publication

Date de publication:
08 2023
Historique:
received: 09 12 2022
revised: 19 06 2023
accepted: 20 06 2023
medline: 29 8 2023
pubmed: 4 8 2023
entrez: 3 8 2023
Statut: ppublish

Résumé

Investigation of the disparities in the access to experimental treatment in early-phase clinical trials is lacking. The objective of the EGALICAN-2 study was to identify the factors underpinning such inequalities. A national prospective survey was conducted in 11 early-phase clinical trial centers (CLIP Between 2015 and 2016, 1355 patients referred from 11 CLIP This study investigated the factors producing social inequalities in the context of early-phase clinical trials in oncology. Our research highlights factors of sex, care pathway and geographic location. Gynecological cancer was found to impact C1D1 significantly, unlike breast cancer. The results of this study should contribute to improve patient access to early-phase clinical trials.

Sections du résumé

BACKGROUND
Investigation of the disparities in the access to experimental treatment in early-phase clinical trials is lacking. The objective of the EGALICAN-2 study was to identify the factors underpinning such inequalities.
METHODS
A national prospective survey was conducted in 11 early-phase clinical trial centers (CLIP
RESULTS
Between 2015 and 2016, 1355 patients referred from 11 CLIP
CONCLUSIONS
This study investigated the factors producing social inequalities in the context of early-phase clinical trials in oncology. Our research highlights factors of sex, care pathway and geographic location. Gynecological cancer was found to impact C1D1 significantly, unlike breast cancer. The results of this study should contribute to improve patient access to early-phase clinical trials.

Identifiants

DOI: 10.1016/j.esmoop.2023.101610 PMID: 37536254 PMC: PMC10415590
pubmed: 37536254
pii: S2059-7029(23)00845-1
doi: 10.1016/j.esmoop.2023.101610
pmc: PMC10415590
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101610

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

E Charton (E)

Human and Social Sciences Department, Centre Léon Bérard, Lyon. Electronic address: emilie.charton@lyon.unicancer.fr.

C Baldini (C)

Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif.

Y Fayet (Y)

Human and Social Sciences Department, Centre Léon Bérard, Lyon; Research on Healthcare Performance (RESHAPE), INSERM U1290, Lyon.

E Schultz (E)

CEPED (UMR 196), University of Paris, IRD, Paris; SESSTIM, CANBIOS Team, Aix-Marseille University, INSERM, IRD, Marseille.

L Auroy (L)

University of Grenoble Alpes, CNRS, Sciences Po Grenoble, Grenoble.

E Vallier (E)

Human and Social Sciences Department, Centre Léon Bérard, Lyon; Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif.

A Italiano (A)

Bergonié Institute, Bordeaux.

M Robert (M)

Medical Oncology Department, Institut de Cancérologie de l'Ouest, Saint-Herblain.

E Coquan (E)

Medical Oncology Department, Centre François Baclesse, Caen.

N Isambert (N)

Medical Oncology Department, University Hospital of Poitiers, Poitiers.

P Moreau (P)

Medical Oncology Department, Centre Georges-François Leclerc, Dijon.

C Touzeau (C)

Department of Hematology, University Hospital of Nantes, Nantes.

C Le Tourneau (C)

Department of Drug Development and Innovation, Institut Curie, Paris.

Z Ghrieb (Z)

Service de Pharmacologie et Investigations Cliniques, Hôpital Saint-Louis, AP-HP, Paris.

J-J Kiladjian (JJ)

Service de Pharmacologie et Investigations Cliniques, Hôpital Saint-Louis, AP-HP, Paris.

J-P Delord (JP)

Institut Claudius Regaud, IUCT-Oncopole, Toulouse.

C Gomez Roca (C)

Institut Claudius Regaud, IUCT-Oncopole, Toulouse.

N Vey (N)

Department of Hematology, Institut Paoli-Calmettes, Marseille.

F Barlesi (F)

CRCM, INSERM, CNRS, APHM, Aix-Marseille University, Marseille; Gustave Roussy, Villejuif.

T Lesimple (T)

Department of Oncology, Eugene Marquis Center, Rennes.

N Penel (N)

Centre Oscar Lambret, Lille University, Lille.

J-C Soria (JC)

Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif.

C Massard (C)

Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif.

S Besle (S)

Human and Social Sciences Department, Centre Léon Bérard, Lyon; Drug Development Department (DITEP), Gustave Roussy, Paris-Saclay University, Villejuif; Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Institut Convergence PLAsCAN, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Inequality factors in access to early-phase...
questionsmedicales.fr › Personnes › Tranches d'âge › Adolescent › Inequality factors in access to early-phase...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Jeune adulte › Inequality factors in access to early-phase...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Inequality factors in access to early-phase...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Inequality factors in access to early-phase...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Inequality factors in access to early-phase...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Inequality factors in access to early-phase...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Inequality factors in access to early-phase...
questionsmedicales.fr › Régions géographiques › Europe › France › Inequality factors in access to early-phase...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Inequality factors in access to early-phase...